About Soligenix (NASDAQ:SNGX)
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$10.45 million
Price / Sales1.64
Price / CashN/A
Book Value$1.35 per share
Price / Book1.45
Return on Equity-112.81%
Return on Assets-71.98%
Soligenix (NASDAQ:SNGX) Frequently Asked Questions
What is Soligenix's stock symbol?
Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
How were Soligenix's earnings last quarter?
Soligenix Inc. (NASDAQ:SNGX) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.15. The biopharmaceutical company had revenue of $1.82 million for the quarter, compared to analyst estimates of $1.36 million. Soligenix had a negative net margin of 90.93% and a negative return on equity of 112.81%. View Soligenix's Earnings History.
When will Soligenix make its next earnings announcement?
Where is Soligenix's stock going? Where will Soligenix's stock price be in 2017?
2 brokers have issued 12 month price targets for Soligenix's stock. Their predictions range from $5.00 to $5.50. On average, they anticipate Soligenix's share price to reach $5.25 in the next year. View Analyst Ratings for Soligenix.
Who are some of Soligenix's key competitors?
Some companies that are related to Soligenix include AEterna Zentaris (AEZS), AzurRx BioPharma (AZRX), Biolase (BIOL), Caladrius Biosciences (CLBS), Proteon Therapeutics (PRTO), Streamline Health Solutions (STRM), ReWalk Robotics (RWLK), Neuralstem (CUR), Genocea Biosciences (GNCA), Invivo Therapeutics (NVIV), EnteroMedics (RSLS), Prana Biotechnology (PRAN), Novus Therapeutics (NVUS), Oncobiologics (ONS), IntelliPharmaCeutics Intl (IPCI), Pernix Therapeutics (PTX), Pain Therapeutics (PTIE) and Tonix Pharmaceuticals (TNXP).
Who owns Soligenix stock?
Soligenix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include
ACT CAPITAL MANAGEMENT, LLLP
SC FUNDAMENTAL VALUE FUND, L.P.
(5.81%). Company insiders that own Soligenix stock include Christopher J Schaber, Jerome B Zeldis, Marco Maria Brughera, Randal J Kirk and Spa Essetifin. View Institutional Ownership Trends for Soligenix.
How do I buy Soligenix stock?
Shares of Soligenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soligenix's stock price today?
One share of Soligenix stock can currently be purchased for approximately $1.96.
How big of a company is Soligenix?
Soligenix has a market capitalization of $17.11 million and generates $10.45 million in revenue each year. The biopharmaceutical company earns $-3,240,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Soligenix employs 19 workers across the globe.
How can I contact Soligenix?
Soligenix's mailing address is 29 EMMONS DRIVE SUITE C-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]
MarketBeat Community Rating for Soligenix (SNGX)MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Soligenix (NASDAQ:SNGX) Earnings History and Estimates Chart
Soligenix (NASDAQ SNGX) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/26/2018|| || || || || || || || |
|11/6/2017||Q3 2017||($0.32)||($0.17)||$1.36 million||$1.82 million||View||N/A|
|8/11/2017||Q2 2017||($0.32)||($0.41)||$1.43 million||$1.00 million||View||N/A|
|5/11/2017||Q1 2017||($0.30)||($0.32)||$1.30 million||View||N/A|
|3/24/2016||Q1||($0.06)||($0.04)||$1.00 million||$2.97 million||View||N/A|
|8/12/2015||($0.10)||($0.15)||$1.00 million||$1.10 million||View||N/A|
|3/24/2015||($0.10)||($0.07)||$0.80 million||$1.93 million||View||N/A|
|11/10/2014||($0.09)||($0.08)||$1.51 million||$2.79 million||View||N/A|
|8/11/2014||($0.09)||($0.05)||$0.80 million||$1.40 million||View||N/A|
|5/12/2014||($0.09)||($0.08)||$0.80 million||$0.90 million||View||N/A|
Soligenix (NASDAQ:SNGX) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.28 EPS
Next Year EPS Consensus Estimate: $-1.5 EPS
Dividend History for Soligenix (NASDAQ:SNGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Soligenix (NASDAQ SNGX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 2.13%
Soligenix (NASDAQ SNGX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/29/2017||Spa Essetifin||Insider||Buy||293,510||$2.12||$622,241.20|| |
|5/8/2017||Randal J Kirk||Major Shareholder||Sell||160,968||$3.12||$502,220.16|| |
|12/16/2016||Christopher J Schaber||CEO||Buy||15,804||$3.16||$49,940.64|| |
|12/16/2016||Marco Maria Brughera||Director||Buy||2,000||$3.16||$6,320.00|| |
|12/23/2015||Jerome B Zeldis||Director||Buy||2,500||$1.27||$3,175.00|| |
|12/22/2015||Christopher J Schaber||CEO||Buy||10,000||$1.29||$12,900.00|| |
|12/22/2014||Joseph Michael Warusz||CFO||Buy||8,265||$1.21||$10,000.65|| |
|6/25/2013||Christopher J Schaber||CEO||Buy||9,523||$1.05||$9,999.15|| |
|6/25/2013||Keith L Brownlie||Director||Buy||19,047||$1.05||$19,999.35|| |
Soligenix (NASDAQ SNGX) News Headlines
|Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX)|
www.americanbankingnews.com - December 15 at 9:32 PM
|Soligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 Million|
www.americanbankingnews.com - December 15 at 2:30 PM
|Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately|
finance.yahoo.com - December 8 at 3:50 PM
|Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX)|
www.americanbankingnews.com - December 2 at 9:56 PM
|Soligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 Shares|
www.americanbankingnews.com - December 1 at 9:02 PM
|Soligenix (SNGX) and ContraFect (CFRX) Head-To-Head Contrast|
www.americanbankingnews.com - November 30 at 3:12 AM
|Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA|
finance.yahoo.com - November 27 at 4:13 PM
|$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter|
www.americanbankingnews.com - November 27 at 8:11 AM
|Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX)|
www.americanbankingnews.com - November 26 at 1:16 AM
|Critical Survey: Soligenix (SNGX) vs. TetraLogic Pharmaceuticals Corporation (TLOG)|
www.americanbankingnews.com - November 23 at 5:46 AM
|Analyzing XOMA Corporation (XOMA) and Soligenix (SNGX)|
www.americanbankingnews.com - November 19 at 5:22 AM
|Who Owns Most Of Soligenix Inc (SNGX)?|
finance.yahoo.com - November 15 at 10:06 AM
|Zacks Investment Research Research Analysts Increase Earnings Estimates for Soligenix Inc. (SNGX)|
www.americanbankingnews.com - November 9 at 7:21 AM
|Soligenix Inc. (SNGX) Expected to Post Quarterly Sales of $1.36 Million|
www.americanbankingnews.com - November 8 at 4:50 AM
|Soligenix Inc. (SNGX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS|
www.americanbankingnews.com - November 7 at 9:06 AM
|-$0.40 EPS Expected for Soligenix Inc. (SNGX) This Quarter|
www.americanbankingnews.com - November 6 at 7:32 PM
|Soligenix Inc. (SNGX) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - November 6 at 11:38 AM
|Soligenix Inc. (SNGX) Earns Buy Rating from HC Wainwright|
www.americanbankingnews.com - November 6 at 11:38 AM
|Soligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market|
finance.yahoo.com - November 4 at 4:05 PM
|Analyzing Grifols, (GRFS) and Soligenix (SNGX)|
www.americanbankingnews.com - November 3 at 3:18 AM
|Soligenix Inc. (SNGX) PT Set at $5.00 by Maxim Group|
www.americanbankingnews.com - October 31 at 2:07 PM
|Soligenix Inc. (SNGX) Given a $5.00 Price Target by Maxim Group Analysts|
www.americanbankingnews.com - October 24 at 7:26 PM
|$1.36 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter|
www.americanbankingnews.com - October 20 at 2:02 PM
| Brokerages Anticipate Soligenix, Inc. (SNGX) to Post -$0.40 Earnings Per Share|
www.americanbankingnews.com - October 18 at 4:08 AM
|Head-To-Head Survey: Soligenix (SNGX) vs. The Competition|
www.americanbankingnews.com - October 6 at 2:06 AM
|Contrasting Epirus Biopharmaceuticals (EPRS) and Soligenix (SNGX)|
www.americanbankingnews.com - October 4 at 2:40 PM
|Critical Contrast: Soligenix (SNGX) & The Competition|
www.americanbankingnews.com - September 30 at 6:26 AM
|Head-To-Head Survey: Soligenix (SNGX) vs. Its Competitors|
www.americanbankingnews.com - September 30 at 12:30 AM
|Comparing Soligenix (SNGX) & The Competition|
www.americanbankingnews.com - September 27 at 10:12 AM
|Soligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate|
finance.yahoo.com - September 27 at 8:44 AM
|Financial Survey: Soligenix (SNGX) vs. Senesco Technologies (SVON)|
www.americanbankingnews.com - September 23 at 10:28 PM
|Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017|
finance.yahoo.com - September 23 at 7:31 AM
|Soligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III Trials|
finance.yahoo.com - September 23 at 7:31 AM
|HC Wainwright Reaffirms Buy Rating for Soligenix Inc. (SNGX)|
www.americanbankingnews.com - September 21 at 5:39 PM
|Maxim Group Reaffirms "Buy" Rating for Soligenix Inc. (SNGX)|
www.americanbankingnews.com - September 20 at 9:46 AM
|Soligenix (SNGX) versus Aevi Genomic Medicine (GNMX) Critical Contrast|
www.americanbankingnews.com - September 18 at 2:26 AM
|Financial Comparison: Soligenix (SNGX) vs. Its Rivals|
www.americanbankingnews.com - September 15 at 2:30 PM
|Contrasting Soligenix (SNGX) and Its Competitors|
www.americanbankingnews.com - September 14 at 6:04 PM
|Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell|
feeds.benzinga.com - August 30 at 11:13 AM
|Reviewing Soligenix (SNGX) & Mateon Therapeutics (MATN)|
www.americanbankingnews.com - August 26 at 10:08 PM
|-$0.37 EPS Expected for Soligenix Inc. (SNGX) This Quarter|
www.americanbankingnews.com - August 23 at 12:10 AM
|Soligenix (SNGX) and Osiris Therapeutics (OSIR) Financial Survey|
www.americanbankingnews.com - August 21 at 10:22 PM
|Soligenix Inc. (NASDAQ:SNGX) Issues Quarterly Earnings Results|
www.americanbankingnews.com - August 12 at 10:40 AM
|$1.43 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter|
www.americanbankingnews.com - August 6 at 7:11 AM
| Brokerages Expect Soligenix Inc. (NASDAQ:SNGX) Will Announce Earnings of -$0.33 Per Share|
www.americanbankingnews.com - August 4 at 6:26 PM
|Soligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing|
finance.yahoo.com - August 2 at 4:38 PM
|Technical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix|
www.prnewswire.com - August 1 at 4:02 PM
|Soligenix Inc. (SNGX) PT Set at $11.00 by HC Wainwright|
www.americanbankingnews.com - July 27 at 10:14 AM
|Mid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide|
www.nasdaq.com - July 19 at 1:47 AM
|Mid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views|
www.nasdaq.com - July 18 at 8:19 AM
Soligenix (NASDAQ:SNGX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Soligenix (NASDAQ:SNGX) Income Statement, Balance Sheet and Cash Flow Statement
Soligenix (NASDAQ SNGX) Stock Chart for Sunday, December, 17, 2017